What does REDPHARMA do?

REDPHARMA is a media agency in Zaventem. Public Limited, started on 9 April 2010, 2 establishments.

What is the address of REDPHARMA?

The registered office of REDPHARMA is located at Da Vincilaan 7, 1930 Zaventem.

Is REDPHARMA still active?

Yes. According to the CBE (29 October 2026) REDPHARMA is active, legal situation “Normale toestand”, started on 9 April 2010.

Is REDPHARMA registered on Peppol?

Yes, REDPHARMA is registered on the Peppol network with ID 0208:0824819011.

What is the enterprise number of REDPHARMA?

The enterprise number of REDPHARMA is BE0824819011.

When was REDPHARMA founded?

REDPHARMA was founded on 9 April 2010.

Who are the directors of REDPHARMA?

According to the 2025 annual accounts, the directors of REDPHARMA are: Clotilde Ghysselinckx, Emmanuel Vanderhaegen, Clément Vanthournhout.

Is REDPHARMA a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 9 April 2010; 5 annual accounts filed, latest fiscal year 2025; 3 directors known from the annual account; 2 establishments in the CBE.

How much profit did REDPHARMA make in 2025?

REDPHARMA posted a profit after taxes of € 2,192,032 in financial year 2025.

What is the revenue of REDPHARMA?

As a small company, REDPHARMA is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 5,535,196.

How much does an employee at REDPHARMA earn?

The average wage cost per full-time employee at REDPHARMA was € 106,500 in 2025: staff costs of € 2.6 million for 24.1 FTE, according to the annual account at the National Bank. That is the employer's cost, not net pay.

How many employees does REDPHARMA have?

According to the 2025 annual accounts, REDPHARMA has 24.1 full-time equivalents (FTE).

Does REDPHARMA have a website?

Yes, REDPHARMA has a website at redpharma.be.

REDPHARMA (Public Limited) - Zaventem - BE0824819011

Dossier REDPHARMA, printed on 29 October 2026 from databakkes.be/en/0824819011/redpharma. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Financials

Financial year 2025

REDPHARMA from Zaventem, company number BE0824819011, closed financial year 2025 with a result of € 2.2 million after tax. For that financial year REDPHARMA recorded a gross margin of € 5.5 million and equity of € 1.4 million. Compared with financial year 2024, the result moved from € 1.5 million to € 2.2 million. Profitable, and profit is growing. The buffer is growing. Debts are under control. The most recent annual accounts were filed with the National Bank of Belgium on July 13, 2026.

What it is worth Growing

€ 1.4 million

▲ 16% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Growing

€ 2.2 million

▲ 47% vs 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 1.1 million

▼ 67% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Pays out

€ 2 million paid out

91 % of the profit went to the shareholders, mostly to IQVIA Solutions Belgium BVBA (100 % of the shares). That is where the money ends up.

People and assets in 2025

Full-time equivalents

24.1

▲ 0.8 vs 2024

Average over the fiscal year, from the social balance sheet.

Wage cost

€ 2.6 million

▲ 1% vs 2024

€ 106,500 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.

Vehicles and equipment

€ 100,317

▼ 7% vs 2024

Book value of vehicles, furniture and equipment.

Debts at end 2025

Bank debt

€ 352,750

▼ 10% vs 2024

Loans from banks and other lenders, long and short.

Owed to suppliers

€ 1.1 million

▲ 2% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Taxes and wages

€ 1.1 million

▲ 8% vs 2024

Taxes, VAT and social contributions still to pay.

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Revenue	€ 8,586,001 Revenue 2022: € 8,586,001 First fiscal year in the series	€ 9,210,749 Revenue 2023: € 9,210,749 ▲ 7% vs 2022 (€ 8,586,001) Favourable step	-	-
Gross margin	-	-	€ 5,854,864 Gross margin 2024: € 5,854,864 First fiscal year in the series	€ 5,535,196 Gross margin 2025: € 5,535,196 ▼ 5% vs 2024 (€ 5,854,864) Unfavourable step	▼ 5%
Profit after taxes	€ 1,493,642 Profit after taxes 2022: € 1,493,642 First fiscal year in the series	€ 1,752,650 Profit after taxes 2023: € 1,752,650 ▲ 17% vs 2022 (€ 1,493,642) Favourable step	€ 1,493,335 Profit after taxes 2024: € 1,493,335 ▼ 15% vs 2023 (€ 1,752,650) Unfavourable step	€ 2,192,032 Profit after taxes 2025: € 2,192,032 ▲ 47% vs 2024 (€ 1,493,335) Favourable step	▲ 47%
Equity	€ 1,920,068 Equity 2022: € 1,920,068 First fiscal year in the series	€ 1,672,718 Equity 2023: € 1,672,718 ▼ 13% vs 2022 (€ 1,920,068) Unfavourable step	€ 1,166,053 Equity 2024: € 1,166,053 ▼ 30% vs 2023 (€ 1,672,718) Unfavourable step	€ 1,358,085 Equity 2025: € 1,358,085 ▲ 16% vs 2024 (€ 1,166,053) Favourable step	▲ 16%
Total debts	€ 5,174,455 Total debts 2022: € 5,174,455 First fiscal year in the series	€ 5,239,623 Total debts 2023: € 5,239,623 ▲ 1% vs 2022 (€ 5,174,455) Unfavourable step	€ 4,668,754 Total debts 2024: € 4,668,754 ▼ 11% vs 2023 (€ 5,239,623) Favourable step	€ 5,128,847 Total debts 2025: € 5,128,847 ▲ 10% vs 2024 (€ 4,668,754) Unfavourable step	▲ 10%
Cash	€ 2,011,884 Cash 2022: € 2,011,884 First fiscal year in the series	€ 3,026,234 Cash 2023: € 3,026,234 ▲ 50% vs 2022 (€ 2,011,884) Favourable step	€ 3,349,326 Cash 2024: € 3,349,326 ▲ 11% vs 2023 (€ 3,026,234) Favourable step	€ 1,097,174 Cash 2025: € 1,097,174 ▼ 67% vs 2024 (€ 3,349,326) Unfavourable step	▼ 67%
Retained profit	€ 1,826,468 Retained profit 2022: € 1,826,468 First fiscal year in the series	€ 1,579,118 Retained profit 2023: € 1,579,118 ▼ 14% vs 2022 (€ 1,826,468) Unfavourable step	€ 1,072,453 Retained profit 2024: € 1,072,453 ▼ 32% vs 2023 (€ 1,579,118) Unfavourable step	€ 1,264,485 Retained profit 2025: € 1,264,485 ▲ 18% vs 2024 (€ 1,072,453) Favourable step	▲ 18%
Dividend	€ 2,000,000 Dividend 2022: € 2,000,000 First fiscal year in the series	€ 2,000,000 Dividend 2023: € 2,000,000 Unchanged (€ 2,000,000) Unchanged	€ 2,000,000 Dividend 2024: € 2,000,000 Unchanged (€ 2,000,000) Unchanged	€ 2,000,000 Dividend 2025: € 2,000,000 Unchanged (€ 2,000,000) Unchanged
Bank debt	€ 506,100 Bank debt 2022: € 506,100 First fiscal year in the series	€ 433,726 Bank debt 2023: € 433,726 ▼ 14% vs 2022 (€ 506,100) Favourable step	€ 393,238 Bank debt 2024: € 393,238 ▼ 9% vs 2023 (€ 433,726) Favourable step	€ 352,750 Bank debt 2025: € 352,750 ▼ 10% vs 2024 (€ 393,238) Favourable step	▼ 10%
Balance sheet total	€ 7,094,522 Balance sheet total 2022: € 7,094,522 First fiscal year in the series	€ 6,912,341 Balance sheet total 2023: € 6,912,341 ▼ 3% vs 2022 (€ 7,094,522) Unchanged	€ 5,834,807 Balance sheet total 2024: € 5,834,807 ▼ 16% vs 2023 (€ 6,912,341) Unchanged	€ 6,486,932 Balance sheet total 2025: € 6,486,932 ▲ 11% vs 2024 (€ 5,834,807) Unchanged	▲ 11%
Employees (FTE)	19 Employees (FTE) 2022: 19 First fiscal year in the series	25.2 Employees (FTE) 2023: 25.2 ▲ 6.2 vs 2022 (19) Unchanged	23.3 Employees (FTE) 2024: 23.3 ▼ 1.9 vs 2023 (25.2) Unchanged	24.1 Employees (FTE) 2025: 24.1 ▲ 0.8 vs 2024 (23.3) Unchanged	▲ 0.8

Key figures of REDPHARMA, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to REDPHARMA?

What happened at REDPHARMA in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

2028 Clotilde Ghysselinckx stepped down as director. NBB
2028 Emmanuel Vanderhaegen stepped down as director. NBB
2028 Clément Vanthournhout stepped down as director. NBB
Jul 13, 2026 New annual accounts for financial year 2025: profit of € 2.2 million (▲ 47% vs 2024). Source: NBB ↗
2023 Emmanuel Vanderhaegen became a director. NBB
2022 Clotilde Ghysselinckx became a director. NBB
2022 Clément Vanthournhout became a director. NBB
Sep 1, 2016 New establishment in Hannut. KBO

In short

From € 1.5 million profit in 2022 to € 2.2 million profit in 2025.

Paid € 2.8 million in corporate taxes since 2022.

Best year ever: 2025, with € 2.2 million profit.

On average € 229,700 of value added per employee in 2025.

Original PDFs at the National Bank ↗

Management

IQVIA Solutions Belgium BVBA 100%

REDPHARMA

The shares are held by IQVIA Solutions Belgium BVBA (100%).

Directors

According to the 2025 annual accounts

Clotilde Ghysselinckx

Bestuurder

since 2022 · until 2028

Emmanuel Vanderhaegen

Bestuurder

Also active at: IQVIA Solutions Belgium, IQVIA RDS & INTEGRATED SERVICES BELGIUM, FORCEA

since 2023 · until 2028

Clément Vanthournhout

Bestuurder

Also active at: IQVIA Solutions Belgium, IQVIA RDS & INTEGRATED SERVICES BELGIUM, Omni Care Consult, FORCEA

since 2022 · until 2028

Shareholders

IQVIA Solutions Belgium BVBA

100%

Participations

No participations in other companies reported.

Establishments

Establishment units

Physical locations of this company

Registered office

Da Vincilaan 7

1930 Zaventem

2.257.771.406

Rue Coquiamont (MER) 11

4280 Hannut

Active since 1 September 2016

Who else lives here?

A building full of entrepreneurs or one very busy letterbox? Another 7 companies are registered at this address.

All companies at this address →

IQVIA Solutions Belgium same network

€ 33.1 million revenue · 2025

TAKEDA BELGIUM

€ 207.4 million revenue · 2026

IQVIA RDS & INTEGRATED SERVICES BELGIUM same network

€ 45.6 million revenue · 2025

IM ASSOCIATES

€ 3.1 million gross margin · 2025

Orifarm Healthcare

€ 31.3 million revenue · 2025

+2 more

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Website

HTTPS redpharma.be

Canonical: https://www.iqvia.com/locations/belgium/solutions/activation-services

Technologies

AOSCloudflare CDNJSFont AwesomeGoogle FontsGoogle Tag ManagerIISSitecorejQuery

Hosting & Email

Email provider

Microsoft 365

Hosting

IQVIA-DURHAM-6A - IQVIA Holdings Inc, US

Website info

HTTPS Ja

Languages EN, FR, NL

Features

Jobs Ads Contact page

Security

✓ HTTPS

✓ SPF

✓ DMARC

Details

Company number: 0824.819.011
VAT number: BE 0824.819.011
Registered office: Da Vincilaan 7, 1930 Zaventem
Names & denominations: REDPHARMA
Enterprise type: Rechtspersoon
Legal form: Public limited company
Legal situation: Normale toestand
Start date: 9 April 2010
Peppol: Active · Active since 1 Jan 2001
Contact: redpharma.be
Activities · NACE: Mediarepresentatie

View on CBE Public ↗ Annual accounts (NBB) ↗

REDPHARMA

Financials

What happened to REDPHARMA?

Management

Directors

Shareholders

Participations

Establishments

Establishment units

Who else lives here?

Website

Technologies

Hosting & Email

Website info

Features

Security

Details

Frequently asked questions